Growth Outcomes of Leuprolide Acetate for Central Precocious Puberty
Author Information
Author(s): Lee Peter A, Neely E Kirk, Fuqua John, Yang Di, Larsen Lois M, Mattia-Goldberg Cynthia, Chwalisz Kristof
Primary Institution: The Milton S. Hershey Medical Center, College of Medicine, Pennsylvania State University
Hypothesis
What is the impact of leuprolide acetate 1-month depot on growth outcomes in children with central precocious puberty?
Conclusion
Leuprolide acetate 1-month depot treatment positively affects growth rate and helps preserve adult height in children with central precocious puberty.
Supporting Evidence
- 29 out of 30 females achieved a mean adult height of 162.5 cm after treatment.
- The mean height gain over baseline predicted adult height was 4.0 cm.
- The study included a long-term follow-up period to assess growth outcomes.
Takeaway
This study shows that a medicine called leuprolide helps kids with early puberty grow taller and reach a normal height when they become adults.
Methodology
This was a prospective, open-label study with a long-term follow-up period, involving 49 females and 6 males treated with leuprolide acetate.
Potential Biases
Potential bias due to the observational nature of the study and reliance on self-reported data for some outcomes.
Limitations
The small number of male participants limits the ability to draw firm conclusions about their outcomes.
Participant Demographics
49 females and 6 males, predominantly Caucasian (61.2%), with a mean age of 7.3 years.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website